Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;11(4):e385.
doi: 10.1002/ctm2.385.

Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta

Sowmya Ramesh  1   2 , Dolly Daniel  3 , Cecilia Götherström  4 , Vrisha Madhuri  1   2
Affiliations
Comment

Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta

Sowmya Ramesh et al. Clin Transl Med. 2021 Apr.

Abstract

The safety of mesenchymal stem cell therapy for osteogenesis imperfecta has been demonstrated previously. However, it is unknown how the trophic effects are mediated by stem cells. In the present commentary, we bring to the attention of readers the recent report by Infante et al in the journal of clinical and translational medicine. The TERCELOI clinical trial presented the possible paracrine effect of transplanted MSCs in vitro and in vivo using proteomics and transcriptomic analysis. This novel finding adds new knowledge in the field of regenerative medicine. However, the scarcity of solid evidence in growth warrants a more thorough discussion.

Keywords: brittle bone disease; growth chart; intraosseous; stem cell therapy.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Growth chart of a male child with severe type III OI. The increase in (A) height and (B) weight from visit 0 to 5 are plotted (blue) on the Indian Academy of Paediatrics and WHO growth chart. The red line indicates the third percentile, while the remaining curves correspond to 10th, 25th, 50th, 75th, 90th, and 97th percentile. The visit 4 indicates the first administration of MSCs (green arrow). Visit 5 refers to 4 months after first dose of MSC administration
FIGURE 2
FIGURE 2
A figure showing the hypothetical in vivo molecular mechanism of mesenchymal stem cells and its action on various cellular functions after administration based on the literature 16 , 17 , 18 and the TERCELOI 6 trial data. Intravenous and intraosseous MSC administration could have direct or indirect effects on increased cell engraftment and bone formation that are mediated by various pathways as stated along with their key players
See this image and copyright information in PMC

Comment on

References

    1. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow‐derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309‐313. - PubMed
    1. Le Blanc K, Götherström C, Ringdén O, et al. Fetal mesenchymal stem‐cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79:1607‐1614. - PubMed
    1. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow‐derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932‐8937. - PMC - PubMed
    1. Shammaa R, El‐Kadiry AEl‐H, Abusarah J, Rafei M. Mesenchymal stem cells beyond regenerative medicine. Front Cell Dev Biol. 2020;8. - PMC - PubMed
    1. Bloor AJC, Patel A, Griffin JE, et al. Production, safety and efficacy of iPSC‐derived mesenchymal stromal cells in acute steroid‐resistant graft versus host disease: a phase I, multicenter, open‐label, dose‐escalation study. Nat Med. 2020;26:1720‐1725. - PubMed